RxDoctor Payments Data

Nina Goyal, MD

Ophthalmology · Chicago, ILNPI 1568578607

Payments from drug & device makers

$32,716in general payments, 2019–2025

Across 96 payments — averaging $340.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sight Sciences, Inc.$23K
  • Johnson & Johnson Surgical Vision, Inc.$3K
  • AbbVie$2K
  • NEW World Medical,inc.$1K
  • Microsurgical Technology, Inc.$1K
  • Alcon$888
  • plus $1K from 15 others

What the payments were for

  • Consulting fees$4,93515%
  • Speaking & faculty fees$21,94667%
  • Travel & lodging$6772%
  • Food & beverage$5,14016%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,716 in reported general payments places this provider in the 90th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$170,029
Medicare patients
527
Services billed
1,595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost19$14,072
RhopressaNetarsudil Mesylate24$12,211
CombiganBrimonidine Tartrate/Timolol25$11,953
Brimonidine Tartrate181$10,920
Latanoprost375$5,087
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$4,824
Brinzolamide15$4,726
Timolol Maleate126$3,437
TafluprostTafluprost/Pf12$2,893
Prednisolone Acetate108$2,858
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat139$2,637
Fluorometholone15$2,486
Travoprost13$1,832
MoxifloxacinMoxifloxacin Hcl79$1,736
Dorzolamide Hcl77$1,255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$118$26,28343 claims
AbbVieCombigan$1,643$11,95325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →